European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Assets

HLP003

formerly CYB003

Helus Pharma

Molecule class
deuterated psilocin analogue (company description)
Mechanism
Not independently verified.
Phase
Phase 3: APPROACH (NCT06564818, US only) COMPLETED on ClinicalTrials.gov, primary completion 2026-09-04 ACTUAL, study completion 2026-10-23 ACTUAL, 223 enrolled, no results posted; EMBRACE (NCT06793397) recruiting; EXTEND (NCT06605105) enrolling by invitation
Indication
major depressive disorder
Sponsor geography
IE
Next catalyst
APPROACH Phase 3 topline, by 2026-12-31
IP status
Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as guided, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

sec.govregistryverified 2026-11-07

Registered trials

  • NCT06605105ClinicalTrials.gov

    PHASE3 · Major Depressive Disorder · ENROLLING_BY_INVITATION · Australia, Greece, Poland, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-10-13

  • NCT06793397ClinicalTrials.gov

    PHASE3 · Major Depressive Disorder (MDD);Depression in Adults;Depression - Major Depressive Disorder;Depression Disorders;Depression Disorder;Depression · RECRUITING · Australia, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-10-06

  • 2024-516805-22-00CTIS

    Therapeutic confirmatory (Phase III) · Major Depressive Disorder · Authorised · Czechia, Germany, Greece, Ireland, Poland

    euclinicaltrials.euctis registryverified 2026-08-31

  • 2024-519270-40-00CTIS

    Therapeutic confirmatory (Phase III) · Major Depressive Disorder · Authorised · Czechia, Germany, Greece, Ireland, Poland

    euclinicaltrials.euctis registryverified 2026-11-07

In the briefing

Issues tagged CYBIN, the owner of this asset.

Record history